PharmacyCodes



Fluvastatinum [Inn-Latin] en es it fr

Fluvastatinum [Inn-Latin] Brand names, Fluvastatinum [Inn-Latin] Analogs

Fluvastatinum [Inn-Latin] Brand Names Mixture

  • No information avaliable

Fluvastatinum [Inn-Latin] Chemical_Formula

C24H26FNO4

Fluvastatinum [Inn-Latin] RX_link

http://www.rxlist.com/cgi/generic2/fluvastatinxl.htm

Fluvastatinum [Inn-Latin] fda sheet

Fluvastatinum_[Inn-Latin] FDA

Fluvastatinum [Inn-Latin] msds (material safety sheet)

Fluvastatinum [Inn-Latin] Synthesis Reference

F. G. Kathawala, U.S. Pat. 4,739,073 (1988)

Fluvastatinum [Inn-Latin] Molecular Weight

411.466 g/mol

Fluvastatinum [Inn-Latin] Melting Point

194-197oC

Fluvastatinum [Inn-Latin] H2O Solubility

0.46 mg/L

Fluvastatinum [Inn-Latin] State

Solid

Fluvastatinum [Inn-Latin] LogP

4.98

Fluvastatinum [Inn-Latin] Dosage Forms

Capsules; Tablets (extended-release)

Fluvastatinum [Inn-Latin] Indication

For management as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels in patients with primary hypercholesterolemia and mixed dyslipidemia

Fluvastatinum [Inn-Latin] Pharmacology

Fluvastatin, the first synthetically-prepared HMG-CoA reductase inhibitor, is used as an antilipemic to lower cholesterol and triglyceride levels associated with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson types IIa and IIb) and to slow the progression of coronary atherosclerosis in patients with coronary artery disease. Although similar to lovastatin, simvastatin, and pravastatin, Fluvastatin has a shorter half-life, no active metabolites, extensive protein binding, and minimal CSF penetration.

Fluvastatinum [Inn-Latin] Absorption

24% (range 9%-50%).

Fluvastatinum [Inn-Latin] side effects and Toxicity

Variety of GI complaints and an increase in transaminase values (i.e., SGOT and SGPT).

Fluvastatinum [Inn-Latin] Patient Information

PATIENT INFORMATION

Patients should be advised to report promptly unexplained muscle pain, tenderness or
weakness, particularly if accompanied by malaise or fever.

Women should be informed that if they become pregnant while receiving Lescol or Lescol
XL the drug should be discontinued immediately to avoid possible harmful effects on a
developing fetus from a relative deficit of cholesterol and biological products derived
from cholesterol. In addition, Lescol or Lescol XL should not be taken during nursing.

Fluvastatinum [Inn-Latin] Organisms Affected

Humans and other mammals